Additional investment will enable animal health company to continue developing product pipeline and delivering affordable, accessible treatments to pet owners
FARMINGTON, Conn., Nov. 16, 2022 /PRNewswire-PRWeb/ — Torigen Pharmaceuticals, Inc, a commercial-stage animal health biologics company, today announced it has closed its $13 million Series A1 round led by Werth Family Investment Associates, LLC and Connecticut Innovations, Inc., bringing the total raised by the company to $18 million. Existing investors Emerald Development Managers, Gaingels, Kema Fund, University of Notre Dame, SoGal Ventures, and UCONN Innovation Fund, LLC participated in the round. New investors in this round also included Ironwood Capital and Advantage Capital. See the full article here.